Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solvonis TherapeuticsFRA:J4I 3-Year ROIIC % is -33.36 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 2,931 Industrial Products companies, Solvonis Therapeutics ranks worse than 83.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Solvonis Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -33.36%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Solvonis Therapeutics's 3-Year ROIIC % or its related term are showing as below:
FRA:J4I's 3-Year ROIIC % is ranked worse than 83.79% of 2931
companies
in the Industrial Products industry
Industry Median: 3.45
vs FRA:J4I: -33.36
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Solvonis Therapeutics 3-Year ROIIC % Related Terms
Solvonis Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Solvonis Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:J4I vs GEV, ETN, PH: 3-Year ROIIC % Comparison
For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solvonis Therapeutics 3-Year ROIIC % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Solvonis Therapeutics's 3-Year ROIIC % falls into.
Solvonis Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.087 (Dec. 2025) - -3.094 (Dec. 2022) )
/
( 6.563 (Dec. 2025) - 3.554 (Dec. 2022) )
=
-0.993
/
3.009
=
-33.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Solvonis Therapeutics (FRA:J4I) has a 3-Year ROIIC % of -33.36 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #2456 out of 2931 companies in the Industrial Products industry, placing it in the top 83.8%.
Is Solvonis Therapeutics' 3-Year ROIIC % too high?
Solvonis Therapeutics' current 3-Year ROIIC % is -33.36. Based on the distribution chart, Solvonis Therapeutics ranks #2456 out of 2931 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' 3-Year ROIIC % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #2456 out of 2931 companies for 3-Year ROIIC %. This places Solvonis Therapeutics in the lower half of its industry. The industry median 3-Year ROIIC % is 3.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for an Industrial Products company?
The median 3-Year ROIIC % among Industrial Products companies is 3.45, based on 2,931 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median 3-Year ROIIC % is 3.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current 3-Year ROIIC % is -33.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (FRA:J4I) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 85% below its estimated fair value. The current 3-Year ROIIC % is -33.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Solvonis Therapeutics (FRA:J4I), the current 3-Year ROIIC % is -33.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J4I has been successfully added to your 
